熱門資訊> 正文
BTIG在第四次裁员后将Bionano评级下调至中性
2024-09-11 01:35
- BTIG downgrades shares of Bionano Genomics (NASDAQ:BNGO) from Buy to Neutral following news that the company has announced its fourth workforce reduction since May 2023.
- BTIG's downgrade call is principally driven by the ongoing challenging capital markets environment, particularly for small cap companies.
- Bionano will part ways with another 45% of its workforce, expected to reduce its annual cash burn by an additional $25-30M, and this includes its newer CFO, Gulsen Kama, to help preserve cash.
- Looking at Seeking Alpha’s Quant rating, BNGO has a score of 2.51 out of 5. The company received D- and F in the prospect of profitability and momentum, respectively, while it got a B in valuation and D+ in growth factors.
- Turning to the Wall Street community sees the stock as a Buy, just 2 analysts gave BNGO a Strong Buy while 0 were with Buy whereas, 2 of them gave the stock a Hold recommendation, and none were on the short side.
More on Bionano Genomics
- Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)
- Bionano Genomics, Inc. (BNGO) Q2 2024 Earnings Call Transcript
- Bionano Genomics files for up to 35M common stock offering by selling securityholders
- Bionano falls after $10M stock offering
- Seeking Alpha’s Quant Rating on Bionano Genomics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
